Nicholas Keen

Years Active: 2021-2022
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma E Mudd, Helen Harrison, Paul J Beswick, Katerine van Rietschoten, Sophie M Watcham, Heather S Scott, Amy N Brown, Peter U Park, Carly Campbell, Eric Haines, Johanna Lahdenranta, Michael J Skynner, Phil Jeffrey, Nicholas Keen, Kevin Lee
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Molecular cancer therapeutics 21 (12) (2022)
Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Eric Haines, Heather Cohen, Elizabeth Repash, Drasti Kanakia, Jun Ma, Julia Kristensson, Fanglei You, Carly Campbell, David Witty, Mike Kelly, Stephen Blakemore, Phil Jeffrey, Kevin McDonnell, Philip Brandish, Nicholas Keen
BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ ( Bicycle TICA™) induces tumor localized CD137 agonism. Journal for immunotherapy of cancer 9 (11) (2022)
Punit Upadhyaya, Johanna Lahdenranta, Kristen Hurov, Sailaja Battula, Rachel Dods, Eric Haines, Marianna Kleyman, Julia Kristensson, Jessica Kublin, Rachid Lani, Jun Ma, Gemma Mudd, Elizabeth Repash, Katerine Van Rietschoten, Tom Stephen, Fanglei You, Helen Harrison, Liuhong Chen, Kevin McDonnell, Philip Brandish, Nicholas Keen
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist. Journal for immunotherapy of cancer 9 (1) (2021)

Nicholas Keen.css-eqlu8i{font-size:small;padding-left:4px;}